尿多酸肽改善晚期癌症患者生活质量的临床研究

目的 评价尿多酸肽注射液对 135例晚期癌症患者生活质量的影响及临床应用价值. 方法 应用欧洲癌症研究与治疗组织推出的生活质量核心量表 EORTC QLQ C 30(V3.0)中文版,采用多中心、开放、非随机的方法,对 135例晚期癌症患者使用尿多酸肽单药治疗,在治疗前后 2, 4, 6周分别进行 1次问卷调查;尿多酸肽注射液深静脉点滴给药, 1次 /d,连续用药 4～ 8周. 结果 尿多酸肽对 135例晚期癌症患者 EORTC QLQ C30(V3.0)15项领域中位有效改善率为 44.5%;其中原发性肝癌、非小细胞肺癌、结直肠癌、乳腺癌、胃癌、食管癌、脑胶质瘤等的 15项领域中位有效改善率分别为 52.9%, 37.0%, 42.9%, 50.0%, 35.8%, 37.5%, 33.3%. 结论 尿多酸肽可明显改善晚期癌症患者的生活质量,在肿瘤临床治疗中具有一定的应用价值.

Effect of uroacitides in improving quality of life of advanced cancer patients

AIM: To evaluate the influences of uroacitides on the quality of life(QOL) in 135 cases of advanced cancer patients and value of clinical application . METHODS: The quality of patients life were also questioned and evaluated using the Chinese version of QLQ C 30 developed the European Organization for Research and Treatment of Cancer (EORTC).This study was designed as a multi center,non randomized open clinical study at 12 different hospitals. Uroacitides was administered as a single agent in a dosage of 300 ml through the deep vein catheter.The 135 patients entered into the study were treated with uroacitides once a day for 4 8 weeks.The clinical benefits(KPS,pain,body,weight,symptoms)and the quality of life were questionnaire survey in 135 patients before and after 2,4,6,8 weeks treatments with uroacitides. RESULTS:The median response rate for 15 scales of EORTC QLQ C 30 was 44.5% among 135 patients.The medians response rates were 52.9% , 37.0% , 42.1% , 50.0% , 35.8% , 37.5% and 33.3% ,respectively in the patients with primary liver cancer,non small cell lung cancer,colorectal cancer,breast cancer,gastric cancer,esophageal cancer and brain tumor. CONCLUSION: Uroacitides can improve the quality of life significantly in advanced cancer patients and have clinical treatment value.